Saxenda Clinical Trials

Browse 29 Saxenda Medical Studies Across 35 Cities

7 Phase 3 Trial · 50 Saxenda Clinics

Reviewed by Michael Gill, B. Sc.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety

Liraglutide 1.8mgfor Type 1 Diabetes Mellitus

Buffalo, NY
18+
All Sexes
The control of glucose homeostasis in subjects with type 1 diabetes is fragile since exogenous insulin cannot compensate for changing requirements and is not precise either in terms of the dose or the bio-availability of the insulin injected. Furthermore, in the near total absence of insulin secretion, the physiological post prandial inhibition of glucagon secretion by the α-cell is also probably deficient in all type 1 diabetics. Thus, there is a need for therapies beyond insulin that can further improve glycemic control and reduce fluctuations in glucose in these subjects. The investigators have recently shown that Liraglutide, a glucagon like peptide (GLP)-1 analogue with duration of action of 24 hours, when added to insulin in subjects with well controlled type 1 diabetes reduces mean and standard deviation of blood glucose, HbA1c and insulin requirements. Since C-peptide concentrations did not alter following Liraglutide, it is likely that the suppression of glucagon may have contributed to this effect. The glucose lowering effects of GLP-1 agonists are well established in subjects with type 2 diabetes, however, these have not been studied prospectively in subjects with type 1 diabetes. The investigators have, therefore, designed this study to investigate the central hypothesis that in patients with type 1 diabetes, Liraglutide has a glucose lowering effect. A major secondary objective of this study is to elucidate the mechanisms responsible for its glucose lowering effects and those involved in reducing the insulin dose. The specific aims of this proposal are: Hypothesis 1: Treatment with Liraglutide in patients with type 1 diabetes decreases HbA1c, fasting, postprandial and the overall mean glucose concentrations while decreasing the dose of insulin required. Aim 1.1: To compare the HbA1c, mean fasting, glucose, mean weekly glucose, standard deviation of weekly blood glucose concentrations as recorded by continuous glucose monitoring and the dose of insulin required prior to and following 52 weeks of treatment with 1.8 mg of liraglutide daily. Aim 1.2: To compare the postprandial glucose concentrations following a test meal before and after 52 weeks of treatment with 1.8 mg of liraglutide daily. Hypothesis 2: Treatment with Liraglutide in patients with type 1 diabetes decreases basal and postprandial glucagon concentrations and increases basal and postprandial C-peptide concentrations. Aim 2.1: To compare the basal and postprandial glucagon and C-peptide concentrations following a test meal before and after 52 weeks of treatment with 1.8 mg of liraglutide daily. Hypothesis 3: Treatment with Liraglutide in patients with type 1 diabetes delays gastric emptying. Aim 3.1: To compare the gastric emptying as measured by acetaminophen absorption before and after treatment with 1.8 mg of daily subcutaneous liraglutide.
Phase 3
Waitlist Available
25 Saxenda Clinical Trials Near Me
Bethesda, MD
Minneapolis, MN
Minneapolis, MN
Dayton, OH
More Trial Locations
An interactive map to display trial locations for National Institutes of Health Clinical Center, University of Minnesota, Delaware Clinical Research Unit, Novo Nordisk Investigational Site, University of North Carolina, and 28 more locations.
Most Popular References for Saxenda Clinical Trials
Frequency
Citation
Top Cities for Saxenda Clinical Trials
City
Active Saxenda Clinical Trials
Top Active Site for Saxenda Clinical Trials
Trial List
Baton Rouge, Louisiana
3
Pennington Biomedical Research Center
Bethesda, Maryland
2
National Institutes of Health Clinical Center
Minneapolis, Minnesota
2
University of Minnesota, Delaware Clinical Research Unit
Baltimore, Maryland
2
Novo Nordisk Investigational Site
Most Recent Saxenda Clinical Trials
Clinical Trial
Began Recruiting Date
Phase
6/21/2021
Phase 2
Phase 3 Saxenda Clinical Trials
Pediatric Saxenda Clinical Trials
Senior Friendly Saxenda Clinical Trials
Clinical Trial
Began Recruiting Date
Phase

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 23rd, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.